Monday, July 24, 2017 5:14:12 PM
Dynavax Technologies Corporation (NASDAQ:DVAX) hepatitis B vaccine Heplisav is nearing the gates of approval, as its August 10th date with destiny, a.k.a. the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) hangs in the wings. William Blair analyst Y Katherine Xu deems 70% probability of approval for the hepatitis B vaccine, and that no matter how the verdict falls, the decision will enable the immune-oncology aspect of the business to set free its true valuation.
Predicting that should Dynavax gain the green light from the FDA, $650 million in peak sales could wait for Heplisav, the analyst reiterates an Outperform rating on DVAX without suggesting a price target. (To watch Xu's track record, click here.)
Xu opines, "Heplisav’s long road to approval should reach its end by August 10, with an FDA panel on July 28 to provide a strong indication of the likelihood of approval. The release of the briefing document on July 26 may affect the stock depending on the content and tone. On a positive outcome, we estimate Dynavax shares to trade above $30 over time, and if negative, the stock could have about 25% downside, since the oncology franchise is providing some floor for the valuation, in our opinion."
Moreover, glancing past prospective approval, "If approved, we believe Heplisav would become standard-of-care in the adult hepatitis B vaccine market, with superior efficacy and an easier dosing schedule as compared with the incumbent Engerix-B (GlaxoSmithKline [GSK $42.42])," continues the analyst.
Ultimately, Xu's conclusion on Dynavax keeps ringing with bullish sentiment, as she contends, "Given the clear superiority in immunogenicity that Heplisav demonstrated over Engerix-B in the overall adult population and in almost all subgroups, we believe the efficacy vote at this panel will be clear cut, and safety will remain the focus of the debate."
Additionally, Simos Simeonidis of RBC Capital rates a Hold rating on DVAX with a $7 price target, marking a nearly 27% downside from where the shares last closed; Phil Nadeau of Cowen rates a Buy on the stock with a $45 price target, marking a 371% increase from where the shares last closed; Michael Yee of Jefferies rates a Hold on the stock with a $4 price target, marking a 58% downside from where the shares last closed; and Anupam Rama of J.P. Morgan rates a Hold on the stock with a $19 price target, marking a nearly 99% increase from where the shares last closed.
Recent DVAX News
- Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 • PR Newswire (US) • 04/24/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:25:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2024 01:17:21 AM
- Dynavax to Present at TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/27/2024 11:54:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:10:48 PM
- Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance • PR Newswire (US) • 02/22/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 11:36:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:45:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:44:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:43:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:42:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:39:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:56:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:46:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:25:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:16:46 PM
- Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024 • PR Newswire (US) • 02/08/2024 09:15:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 02/08/2024 01:41:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:45:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:33:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:32:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 09:31:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/19/2024 07:40:54 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/18/2024 03:10:07 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM